Danish pharmaceutical company Novo Nordisk has identified Australia as a key target for the expansion of its oral weight-loss medication, Wegovy. This strategic interest follows the product’s recent successful launch in the United Kingdom, where it has already seen significant market uptake.
The oral version of the drug is viewed by health professionals as a potential alternative to the current weekly injectable treatments, such as Ozempic and Wegovy. While Novo Nordisk has not provided a formal timeline for an Australian release, the company confirmed that it is closely monitoring local demand and preparing its market entry strategy. Any potential launch remains contingent on formal approval from Australia’s national medicines regulator, a mandatory step before the medication can be prescribed to patients.
Novo Nordisk executives have expressed confidence in the pill’s prospects, citing strong performance data from the United States and the UK. As obesity management remains a critical public health priority, the introduction of an oral treatment could represent a significant shift in how Australian patients access weight-loss therapies, potentially reducing the reliance on injectable formats.